ArticleClinical ophthalmology (Auckland, N.Z.)2016
Transzonular vitreous injection vs a single drop compounded topical pharmaceutical regimen after cataract surgery.
Article in Clinical ophthalmology (Auckland, N.Z.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04200651 (Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Efficacy and safety of dropless cataract surgery.Indian journal of ophthalmology · 2020Trial
- Dropless after cataract surgery (DACS): concepts, evidence and clinical potential.Eye (London, England) · 2026Review
- Sustainability in Cataract and Refractive Surgery: Current Challenges and Future Perspectives.Journal of ophthalmology · 2025Review
- Visual Outcomes and Safety Profile of "Dropless Vitrectomy" for Epiretinal Membranes.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Investigating recent advances in pharmacotherapy for acute and chronic ocular pain post-cataract surgery.Expert opinion on pharmacotherapy · 2024Article
- Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems.Nature reviews. Drug discovery · 2023Review
- Efficacy and safety of 'dropless vitrectomy surgery' and comparison of outcomes to standard of care topical therapy.Frontiers in ophthalmology · 2023Article
- Intravitreal moxifloxacin injections in acute post-cataract surgery endophthalmitis: Efficacy and safety.Indian journal of ophthalmology · 2021Article
- Short-Term Non-Infectious Outcomes After a Pars Plana Intravitreal Antibiotic-Steroid Injection of Triamcinolone, Moxifloxacin, and Vancomycin During Cataract Surgery versus a Standard Postoperative Topical Regimen.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- Comparing Combination Drop Therapy to a Standard Drop Regimen After Routine Cataract Surgery.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- Response to: Transzonular drug delivery during cataract surgery: Is dropless cataract surgery really beneficial?Indian journal of ophthalmology · 2018Article
- Transzonular drug delivery during cataract surgery: Is dropless cataract surgery really beneficial?Indian journal of ophthalmology · 2018Article
- Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy.Clinical ophthalmology (Auckland, N.Z.) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the relative effectiveness of a Tri-Moxi-Vanc intraocular solution injected transzonularly into the vitreous with the topical formulation of Pred-Moxi-Ketor (given for the first week postoperatively) followed by Pred-Ketor (given for weeks 2-4 after surgery). PATIENTS AND
methodsThis was a single-site, single-surgeon, prospective, randomized, subject-masked contralateral eye study with an active comparator and was approved by an appropriate ethics committee. Twenty-five subjects with uncomplicated cataract who were scheduled for cataract surgery were enrolled. If surgery was uneventful, subjects received either an injection in that eye or followed a minimum drop postoperative pharmaceutical regimen. The second eye surgery was performed with the opposite treatment. Subjects were followed for 1 month. Measures of interest were the changes in intraocular pressure (IOP) from baseline and the changes in corneal and macular thickness. Subjects were also asked to evaluate pain perception, visual quality, and overall satisfaction with surgery. They were also asked which regimen they preferred.
resultsIOP was not statistically significantly different between the groups (P=0.81); there was also no statistically significant difference in IOP over time (P=0.74). There was no statistically significant difference in central macular thickness at 1 week and 1 month between the groups (P=0.18). The central corneal thickness was significantly greater 1 day postoperatively relative to baseline, but there was no statistically significant difference between the groups at any time point (P=0.92). The difference in reported pain was also not statistically significantly different between the groups (P=0.67). Satisfaction with surgery was similar for both groups, but significantly more subjects preferred the injection for overall experience (P<0.01).
conclusionCataract surgery completed with the two pharmaceutical regimens was similar in outcome. Significantly more subjects preferred the injection, presumably as a function of the greater convenience with no apparent difference in the therapeutic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.